IL5 and asthma: For IL-5 inhibitors, improvements in FEV1 (mean difference [MD], 0.11; 95% CI, 0.11 to 0.12), Asthma Control Questionnaire scores (MD, −0.4; 95% CI, −0.41 to −0.38), annual exacerbation rates (MD, −0.46; 95% CI, −0.48 to −0.45), and oral corticosteroid use (MD, −50; 95% CI, −52.58 to −47.42) favored biologic treatment.